{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:42:11Z","timestamp":1793954531615,"version":"4.8.0"},"reference-count":27,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ocular Immunology and Inflammation"],"published-print":{"date-parts":[[2018,11,17]]},"DOI":"10.1080\/09273948.2017.1335756","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T17:57:08Z","timestamp":1505411828000},"page":"1206-1211","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation"],"prefix":"10.1080","volume":"26","author":[{"given":"Wajiha J.","family":"Kheir","sequence":"first","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Joe","family":"Mehanna","sequence":"additional","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maamoun","family":"Abdul Fattah","sequence":"additional","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al Ghadban","sequence":"additional","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"El Sabban","sequence":"additional","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad M.","family":"Mansour","sequence":"additional","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola N.","family":"Hamam","sequence":"additional","affiliation":[{"name":",","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.06.004"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2007.0104"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.018"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301401"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302292"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu266"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2011.633205"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"e_1_3_2_11_1","first-page":"1","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"6736","author":"Nguyen QD","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2016;6736(VisualIi):1\u201310.","journal-title":"Lancet (London, England)"},{"key":"e_1_3_2_12_1","first-page":"1","article-title":"Adalimumab for ocular inflammation","volume":"22","author":"Durrani K","year":"2016","unstructured":"Durrani K, Kempen JH, Ying G-S, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. March. 2016;22:1\u20138.","journal-title":"Ocul Immunol Inflamm. March"},{"key":"e_1_3_2_13_1","unstructured":"Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)\u2013\u2013Humira (adalimumab) injection."},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.829109"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.990041"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.03.035"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0199"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74235-7"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"issue":"8697","key":"e_1_3_2_20_1","first-page":"1078","article-title":"International study group for Beh\u00e7et\u2019s disease","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease. International study group for Beh\u00e7et\u2019s disease. Lancet (London, England). 1990;335(8697):1078\u20131080.","journal-title":"Lancet (London, England)"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0180"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S15696"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5939"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.12.011"},{"issue":"3","key":"e_1_3_2_25_1","first-page":"151","article-title":"Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor","volume":"29","author":"Hay H","year":"1989","unstructured":"Hay H, Cohen J. Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. J Clin Lab Immunol. 1989;29(3):151\u2013155.","journal-title":"J Clin Lab Immunol"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1998.0492"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.29.18117"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2013.06.034"}],"container-title":["Ocular Immunology and Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09273948.2017.1335756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:03:41Z","timestamp":1770375821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09273948.2017.1335756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,11,17]]}},"alternative-id":["10.1080\/09273948.2017.1335756"],"URL":"https:\/\/doi.org\/10.1080\/09273948.2017.1335756","relation":{},"ISSN":["0927-3948","1744-5078"],"issn-type":[{"value":"0927-3948","type":"print"},{"value":"1744-5078","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ioii20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ioii20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}